Navigation Links
Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management
Date:11/28/2007

NEW YORK, Nov. 28 /PRNewswire/ -- Carl Marks & Co. LP has partnered with BlueStar Capital Management LP to launch the BlueStar CM Life Sciences Focus Fund LP. The partnership also gives Carl Marks a stake in BlueStar Capital Management, which invests in healthcare hedge funds, and an increased presence in the healthcare investment sector.

The new Focus Fund invests in highly concentrated portfolios which are long and short public healthcare equities, in both managed accounts and limited partnerships.

"We feel the healthcare market provides attractive and solid investment opportunities," said Mark Claster, president of Carl Marks & Co., "and BlueStar Capital Management's long experience with healthcare hedge funds makes this the perfect strategic relationship for our investment interests."

Carl Marks's Andrew Boas will join BlueStar Capital's Advisory Board. Boas is a principal of Carl Marks Management Company.

Jonathan Lach of BlueStar Capital said, "The Focus Fund is invested in the best ideas of some of the best investors in public healthcare equities, a sector that is rich with investment opportunity. We are very pleased to be partnering with Carl Marks, an extremely fine firm with much to contribute to our mutual success."

About Carl Marks & Co.

Founded in 1925, Carl Marks began as a dealer of foreign securities in the United States. The company has diversified into a multi-faceted investment and advisory services firm offering a range of specialized services, including corporate revitalization and investment banking, distressed securities, private equity, real estate and asset management. For more information, visit http://www.carlmarks.com.

About BlueStar Capital Management LP

BlueStar Capital Management LP invests primarily in healthcare hedge funds and provides investment and consulting services for its clients in this dynamic investment sector. The firm manages BlueStar Life Sciences LP, a healthcare sector of funds, and BlueStar CM Life Sciences Focus Fund LP, which invests in a more concentrated manner in the healthcare sector. Additional information about BlueStar Capital Management is available at http://www.bluestar-capital.com.


'/>"/>
SOURCE Carl Marks & Co. LP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
2. Social Network for Scientists Marks Ten Years Online
3. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
4. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):